Jacob Glanville’s Post

"If our data looks good by the end of this year, effectively, the pandemic era for influenza is over," Glanville says. As reported in the Axios exclusive by Katherine Davis, while our Phase I trial is ongoing, we’ve raised another $37M to accelerate through Phase 2, deploy scalable manufacturing innovations, and advance the follow-on portfolio. huge thanks to Structure Fund led, joined by Meiji Seika Pharma Co., Sigmas Group, Kendall Capital Partners, and Stripe founders Patrick and John Collison. Following our Series A with Future Ventures last year, with follow-on by our longest and largest shareholder NFX, GHIC, and others, and our Phase I clinical start at the beginning of this year, this new acceleration capital positions us to 1) move our universal flu program immediately into Phase 2 studies in early 2027 following completion of the current ongoing Phase I (led by CMO Jerry Sadoff). This is an outstanding timing opportunity to advance immediately to Phase 2 without pausing for another fund-raise or non-dilutive in between, which gets us through additional key clinical inflection and much closer to approval. 2) accelerate our four follow-on programs through completion of preclinical characterization and poised for GMP manufacturing (led by CSO Sawsan Youssef, Senior Director Sangil Kim and others). This positions us to advance the next universal immunity medicine from our platform into GMP and clinical development in 2027, further demonstrating the profound generalizability of our platforms to make disruptive 21st century medicines. 3) accelerate our solid phase continuous flow scalable manufacturing process innovation into GMP in 2026, for use with both Centi-Flu consistency lots and also to accelerate and greatly reduce cost and time for manufacturing every one of our follow-on programs (led by CINO Gusti Zeiner and Director of CMC Atsuko Sakurai-Sangria). Being able to do this now is huge for accelerating Centi-Flu to approval and global access, but also huge for having this technology stack deployed in GMP to dramatically lower the cost, time, and risk barriers of entry to clinical for every one of our follow on programs. Steve Jurvetson Omri Amirav-Drory Emilio Emini Helen McBride, Ph.D. Patrick Collison Stephanie Wisner Omri Amirav-Drory Anastasia Budinskaya Pamela Garzone, Ph.D. https://lnkd.in/gTQ6sCPe